Verteporfin v placebo before dynamic phototherapy for neovascular age related macular degeneration*
| Weighted event rates | ||||
|---|---|---|---|---|
| Outcomes | Verteporfin | Placebo | RRR (95% CI) | NNT (CI) |
| *Abbreviations defined in glossary; weighted events, RRR, RRI, NNH, and CI calculated from data in article. | ||||
| ⩾3 lines of vision lost at 24 months | 50% | 64% | 23% (13 to 31) | 8 (5 to 13) |
| ⩾6 lines of vision lost at 24 months | 22% | 36% | 38% (24 to 50) | 8 (5 to 13) |
| RRI (CI) | NNH (CI) | |||
| Visual disturbances | 29% | 18% | 61% (24 to 109) | 10 (6 to 17) |
| Problem with injection site | 13% | 5.6% | 134% (43 to 282) | 15 (10 to 25) |
| Infusion related back pain | 2.0% | 0% | 721% (9 to 6060) | 50 (25 to 100) |
| Photosensitivity reactions | 2.3% | 0.3% | 431% (0 to 2717) | 50 (25 to 100) |